Amarin Corporation plc (NASDAQ:AMRN) Q1 2024 Earnings Conference Call May 1, 2024 8:00 AM ET Company Participants Mark Marmur – Vice President, Corporate Communications and Investor Relations Patrick Holt – President and Chief Executive Officer Jonathan Provoost – Chief Legal and Compliance Officer Steve Ketchum – President-R&D and Chief Scientific Officer Tom Reilly – Chief Financial Officer Conference Call Participants Roanna Ruiz – Leerink Partners Paul Choi – Goldman Sachs Operator Good day, and welcome ...

Exhibit 99.1 Amarin Reports First Quarter 2024 Business Update and Financial Results -- New VAZKEPA® Patent Issued by European Patent Office Extends Intellectual Property Protection in Europe Until 2039 -- -- In Europe, ~35% Revenue Growth, ~65% In-Market Sales Growth Q1 '24 versus Q4 '23 Driven by Spain and the UK -- -- Current Cash Position of $308 Million; Remains Stable Over Seven Quarters -- -- Share Repurchase Program of up to $50 Million Approved by Shareholders; Repurchases Expected to Commence Foll ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-21392 Amarin Corporation plc (Exact Name of Registrant as Specified in its Charter) England and Wales Not applicable (State or Other Jurisdict ...

DUBLIN, Ireland and BRIDGEWATER, N.J., April 24, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced its support for a petition filed with the U.S. Food and Drug Administration (FDA) requesting that the Commissioner focus on and take further action to address significant off-label prescribing of fenofibrates, due to the fact that multiple clinical trials have proven fenofibrates have no clinical benefit when used in combination with statins to reduce cardiovascular disease (CVD) ri ...

DUBLIN, Ireland and BRIDGEWATER, N.J., April 22, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced shareholder approval of all proposed resolutions specified at its 2024 Annual General Meeting (AGM). Importantly, shareholders approved each of the two proposals required for the Company to proceed with its previously announced intent to pursue a share repurchase program of up to $50 million. This permits the Company to request U.K. High Court approval, as required under U.K. compan ...

-- Findings Presented on VASCEPA/VAZKEPA Utility in REDUCE-IT Patient Subgroups by Baseline High/Low Lp(a), LDL-C Levels -- -- Lp(a) Results Published Simultaneously in the Journal of the American College of Cardiology (JACC) – DUBLIN, Ireland and BRIDGEWATER, N.J., April 06, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today highlighted two data presentations at ACC.24 describing the effects of VASCEPA®/VAZKEPA® (icosapent ethyl) on reducing MACE (Major Adverse Cardiovascular Events) in p ...

Shares of Amarin Corporation (AMRN) rose 7.1% on Wednesday after management announced positive updates on its intellectual property portfolio for its sole marketed drug, Vazkepa, in Europe.Amarin obtained a new patent covering Vazkepa from the European Patent Office (EPO). The latest patent adds another eight years to the drug’s regulatory exclusivity in Europe, extending the commercial protection across the continent till April 2039.Along with the above news, management succeeded in defending another one o ...

There was unambigously good news about the company's single commercialized medication.Any one-product company that receives good news about that product will likely attract investors. That was the case Wednesday with Amarin (AMRN 7.07%), which received very encouraging news about its single commercialized drug that day. As a result, its shares were trading more than 6% higher in late-session trading on the stock market, eclipsing the basically flatlining S&P 500 index.A victory for VazkepaAmarin announced t ...

DUBLIN, Ireland and BRIDGEWATER, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company received a Decision to Grant from the European Patent Office (EPO) for a new patent covering VAZKEPA® (icosapent ethyl) that will extend VAZKEPA exclusivity eight additional years into 2039. In addition, the Company recently achieved success defending a separate European VAZKEPA patent from third-party opposition within the EPO. Collectively, these patents cover bot ...

Amarin Corporation Plc (AMRN) reported break-even quarterly earnings in fourth-quarter 2023 against the Zacks Consensus Estimate of a loss of 4 cents per share. The company recorded adjusted earnings of 2 cents in the year-ago quarter.Adjusted earnings exclude non-cash stock-based compensation, restructuring inventory and other restructuring expenses.Total revenues were $74.7 million, beating the Zacks Consensus Estimate of $72.5 million. However, revenues were down 17% from the year-ago quarter’s levels, o ...